Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Cash & Equivalents (2022 - 2025)

Cellebrite DI (CLBT) has 4 years of Cash & Equivalents data on record, last reported at $124.5 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 35.06% year-over-year to $124.5 million; the TTM value through Dec 2025 reached $124.5 million, down 35.06%, while the annual FY2025 figure was $124.5 million, 35.06% down from the prior year.
  • Cash & Equivalents reached $124.5 million in Q4 2025 per CLBT's latest filing, down from $191.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $191.7 million in Q4 2024 and bottomed at $87.6 million in Q4 2022.
  • Average Cash & Equivalents over 4 years is $148.3 million, with a median of $157.0 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: soared 116.23% in 2023, then plummeted 35.06% in 2025.
  • A 4-year view of Cash & Equivalents shows it stood at $87.6 million in 2022, then skyrocketed by 116.23% to $189.5 million in 2023, then increased by 1.13% to $191.7 million in 2024, then tumbled by 35.06% to $124.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $124.5 million in Q4 2025, $191.7 million in Q4 2024, and $189.5 million in Q4 2023.